Skip to main content

Table 1 Demographic details of patients

From: Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia

  Control AD–MB AD+MB VaD
N 21 25 25 21
Sex, female:male 10:11 10:15 11:14 7:15
MMSEa 28.5 ± 1.4 21.7 ± 4.3 18.44 ± 5.5 23.50 ± 3.9
Age 65.9 ± 6.1 67.8 ± 6.3 67 ± 7.7 68.6 ± 6.6
Aβ42 (pg/ml) 803 (1057–675) 500 (612–423) 408 (491–304) 606 (868–424)
tTau (pg/ml) 313 (442–240) 615 (743–430) 567 (784–396) 361 (498–196)
pTau (pg/ml) 53 (73–46.50) 85 (109–66.5) 89 (105–68.5) 50 (65–31)
VEGF (pg/ml) 2.7 (3.4–2.3) 2.8 (3.6–2.4) 2.7 (3.2–2.5) 3.1 (3.9–2.6)
  1. MMSE scores and age presented as mean ± standard deviation. Cerebrospinal fluid biomarkers presented as median (interquartile range)
  2. Aβ42 beta-amyloid, AD–MD Alzheimer’s disease without microbleeds, AD+MB Alzheimer’s disease with microbleeds, MMSE Mini-Mental State Examination, pTau phosphorylated tau, tTau total tau, VaD vascular dementia, VEGF vascular endothelial growth factor
  3. aA 30-point questionnaire to assess cognitive health